3d
Clinical Trials Arena on MSNGilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Promising multiple dose PK data continue to support 4-weekly dosing FDA advice received supporting phase 2 design in HS ...
Clinical trials are notoriously expensive, with operational expenses ranging from $50 million to over $115 million. 1 The ...
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
New results from the phase 1 clinical trial, now published in the journal Nature, show that the therapeutic cancer vaccine activated tumor-specific immune cells that persisted in the body up to nearly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results